Is Ashwagandha Bad for Your Kidneys?

Is Ashwagandha Bad for Your Kidneys?

For most healthy adults, ashwagandha is not bad for the kidneys. Clinical trials using KSM-66 at 300–600 mg daily have not reported kidney toxicity as an adverse event. However, isolated case reports describe acute kidney injury in people taking high doses or low-quality extracts, and individuals with pre-existing kidney disease should consult a nephrologist before use.

---

What Ashwagandha Actually Does in the Body

Ashwagandha (Withania somnifera) is an Ayurvedic adaptogen whose primary active compounds — withanolides, withaferins, and sitoindosides — modulate the hypothalamic-pituitary-adrenal (HPA) axis, reduce cortisol output, and exert antioxidant effects across multiple organ systems. The most studied commercial extract, KSM-66, is standardized to ≥5% withanolides and has accumulated the strongest clinical safety file of any ashwagandha product.

In a 60-day, randomized, double-blind, placebo-controlled trial of 64 adults under chronic stress, KSM-66 at 300 mg twice daily significantly reduced serum cortisol (by roughly 27.9% vs. 7.9% in placebo), improved self-reported stress and anxiety scores, and showed no clinically meaningful changes in hematological or metabolic safety markers — including creatinine and blood urea nitrogen (BUN), the two primary kidney function indicators (Chandrasekhar et al., Indian Journal of Psychological Medicine 2012; PMID: 23439798).

A separate 8-week safety study in 80 healthy adults receiving 300 mg of ashwagandha root extract twice daily found no significant adverse effects on liver enzymes, kidney function markers, or vital signs (Pratte et al., Journal of Alternative and Complementary Medicine 2014; PMID: 25405892). These findings are broadly consistent across the published literature: at recommended doses, ashwagandha does not damage renal tubules or impair glomerular filtration.

---

The Case Reports: When Kidney Problems Do Appear

The reassuring clinical-trial data above comes with an important asterisk. Pharmacovigilance databases and the published case-report literature contain a small but growing number of accounts linking ashwagandha to acute kidney injury (AKI) and interstitial nephritis.

A 2020 case report in American Journal of Kidney Diseases documented a 32-year-old man who developed acute interstitial nephritis after taking 1,350 mg of a non-standardized ashwagandha supplement for three weeks. Kidney biopsy confirmed immune-mediated inflammation. The supplement was discontinued, and kidney function partially recovered over several months — but did not fully normalize (Rasool et al., American Journal of Kidney Diseases 2020; PMID: 32807469).

Several patterns emerge across these case reports:

• Doses above 1,000 mg/day of non-standardized extracts appear in most reports
• Adulterated or contaminated products (heavy metals, undisclosed additives) are implicated in some cases
• Pre-existing autoimmune conditions may increase susceptibility to immune-mediated nephritis
• Concurrent NSAID use — which is itself nephrotoxic — may amplify risk

This does not mean ashwagandha causes kidney disease at normal doses; it means that dose, product quality, and individual health status matter enormously.

---

KSM-66 Ashwagandha Dosage: What the Clinical Evidence Supports

KSM-66 is the extract form most rigorously evaluated for both efficacy and safety, and dose matters more than almost any other variable when assessing kidney risk.

The Chandrasekhar 2012 RCT used 600 mg/day total and remains one of the most cited safety benchmarks. A 2019 study by Choudhary et al. in Journal of the International Society of Sports Nutrition (PMID: 31308396) used 600 mg KSM-66 daily for 8 weeks in resistance-trained men and found no kidney function abnormalities alongside significant improvements in muscle recovery and testosterone.

The practical takeaway: 300–600 mg of a standardized, third-party-tested KSM-66 extract is where safety data accumulates most strongly. Doses beyond that range — especially from bulk powders or unstandardized root powder — are where the risk profile becomes uncertain.

If you're tracking your supplement stack against blood work, an AI-driven platform like Ones can cross-reference your kidney function markers (creatinine, eGFR, BUN) against your formula to flag any ingredient that warrants a closer look at your actual dosing level.

---

KSM-66 Ashwagandha Overdose Symptoms: How to Recognize Too Much

While "overdose" in the pharmacological sense is not well-defined for ashwagandha, excessive intake produces a recognizable symptom cluster that can serve as an early warning:

Gastrointestinal effects (most common):

• Nausea, vomiting, or diarrhea — often the first sign that the dose is too high
• Abdominal cramping and loose stools

Thyroid overstimulation:

• Ashwagandha raises T3 and T4 in some individuals (Sharma et al., Journal of Pharmacy and Pharmacology 2018; PMID: 29063202). People with hyperthyroidism or Graves' disease can experience palpitations, heat intolerance, and anxiety at doses that would be entirely benign for someone with normal thyroid function.

Hepatotoxicity signals:

• Rare but documented jaundice and elevated liver enzymes — a reminder that hepatic and renal metabolism are interconnected. If the liver is stressed, kidney filtration load can increase as a downstream effect.

Renal warning signs specifically:

• Decreased urine output or dark-colored urine
• Flank pain or lower back discomfort not related to exercise
• Peripheral edema (swelling in ankles or feet)
• Fatigue disproportionate to activity level

Any combination of these symptoms during ashwagandha supplementation should prompt stopping the supplement and checking creatinine and BUN. If you're monitoring micronutrient gaps alongside your supplement stack, it's also worth noting that some deficiency patterns — like low vitamin C levels — can compound oxidative stress on the kidneys, making early detection of all nutrient gaps important.

---

Signs of KSM-66 Ashwagandha Deficiency: Is There Such a Thing?

Strictly speaking, ashwagandha is not an essential nutrient, so "deficiency" doesn't apply the way it does to vitamins or minerals. However, many people ask about this because they notice a meaningful difference when they stop taking it — particularly in stress resilience, sleep quality, and energy. This is not a deficiency; it is the loss of an adaptogenic effect.

That said, when people search for "signs of KSM-66 ashwagandha deficiency," they are usually describing the symptoms that led them to try ashwagandha in the first place — symptoms of HPA axis dysregulation:

• Persistent fatigue despite adequate sleep
• Elevated morning cortisol or a flat diurnal cortisol curve
• Poor stress resilience and irritability
• Disrupted sleep architecture (difficulty entering deep sleep)
• Reduced exercise performance and slow recovery

These are not caused by lacking ashwagandha; they indicate underlying cortisol dysregulation or adrenal burden that ashwagandha can help correct. Similarly, if you're noticing symptoms associated with other micronutrient shortfalls — for instance, the neuromuscular signs of magnesium oxide deficiency often mimic adrenal fatigue — it's worth ruling out nutritional gaps before attributing everything to cortisol.

---

KSM-66 Ashwagandha Deficiency Symptoms vs. Other Nutrient Gaps

Because ashwagandha targets the HPA axis and adrenal function, its symptom overlap with actual nutrient deficiencies is broad. The table below helps differentiate:

The overlap is substantial, which is exactly why blood-work-based personalization matters. A platform like Ones uses your actual lab data to determine whether your fatigue is driven by cortisol burden, a mineral gap, or both — and builds a formula to address the specific finding rather than a generic stack.

For broader context on nutritional gaps that mimic adrenal symptoms, it's worth reviewing thiamine deficiency symptoms and lab tests and signs of zinc picolinate deficiency, since both can present with stress-sensitive fatigue patterns.

---

Who Should Avoid or Limit Ashwagandha?

Even at clinically supported doses, certain populations carry elevated risk:

1. People with chronic kidney disease (CKD stages 3–5): Reduced glomerular filtration rate means any bioactive compound is cleared more slowly, extending exposure and increasing the chance of accumulation effects.
2. Those on immunosuppressive therapy: Ashwagandha has immunomodulatory activity that could theoretically interfere with drugs like tacrolimus or cyclosporine — medications often used post-kidney transplant.
3. Pregnant women: Ashwagandha has uterotonic activity in animal models; it is not recommended during pregnancy.
4. Individuals with hyperthyroidism: As noted above, thyroid stimulation at moderate-to-high doses can be problematic.
5. People with autoimmune kidney disease: Immune modulation from ashwagandha could theoretically exacerbate IgA nephropathy or lupus nephritis, though clinical data is insufficient to quantify this risk.

If you fall into any of these categories, consult a nephrologist or endocrinologist before beginning ashwagandha supplementation.

---

What This Means for Your Formula

For the large majority of people without pre-existing kidney or thyroid disease, ashwagandha at 600 mg KSM-66 is well-tolerated and clinically meaningful for cortisol reduction, sleep quality, and recovery. Ones includes KSM-66 ashwagandha at 600 mg — the dose used in the strongest published RCTs — when a user's data indicates HPA axis burden, elevated cortisol markers, or poor stress resilience signals from wearable data.

Critically, Ones does not apply ashwagandha by default. The AI practitioner cross-references your uploaded blood work and health history before including any adaptogen. If your eGFR is flagged or your health intake indicates kidney disease, ashwagandha would not appear in your formula.

For people whose data shows high-cortisol fatigue alongside adrenal burden, Ones also offers its proprietary Adrenal Support blend, which combines complementary botanicals designed to support HPA axis regulation — a more layered approach than a single-ingredient ashwagandha dose. For users whose cortisol pattern intersects with thyroid findings, the AI may instead prioritize Thyroid Support ingredients, avoiding the thyroid-stimulating effect of ashwagandha altogether.

This is the core value of personalized supplementation: the same herb that helps one person can be contraindicated for another, and generic stacks can't make that distinction.

---

Key Takeaways

• At clinical doses (300–600 mg KSM-66 daily), ashwagandha does not damage kidneys in healthy adults — multiple RCTs show no significant changes in creatinine or BUN.
• Doses above 1,000 mg/day from non-standardized or low-quality sources are associated with rare but documented cases of acute kidney injury and interstitial nephritis.
• Red-flag symptoms include dark urine, flank pain, reduced urine output, or peripheral edema — stop supplementing and check kidney markers if these appear.
• "Deficiency" symptoms (fatigue, poor stress resilience, disrupted sleep) reflect HPA axis dysregulation, not a true nutrient deficiency — rule out magnesium, thiamine, and zinc gaps first.
• Higher-risk groups include people with CKD, autoimmune kidney disease, hyperthyroidism, or those on immunosuppressive medications — consult a specialist before use.
• Personalized, data-driven formulation — like the approach Ones takes — ensures ashwagandha is only included when your specific lab markers and health history support its use.

---

This article is for informational purposes only and does not constitute medical advice. Consult a qualified healthcare provider before starting or changing any supplement regimen, especially if you have a pre-existing medical condition.